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See page 1378 for the editorial comment on this articleAims Polymorphisms in the RANTES (G-403A), monocyte chemoattractant protein-1
(MCP-1; A-2518G), stromal cell-derived factor-1b (SDF-1b; G801A), and C–C chemo-
kine receptor-5 (CCR5; D32) genes have been associated with functional effects.
These chemokines have been implicated in leucocyte recruitment to arterial lesions.
In a case-control study, we explored relations between these polymorphisms and
coronary artery disease (CAD), with respect to angiographic abnormalities and acute
coronary syndromes (ACS).
Methods and Results The LUdwigshafen Risk and Cardiovascular health (LURIC) co-
hort was genotyped by RFLP-PCR. Based on coronary angiography, individuals were
sub-divided into CAD cases ðn ¼ 2694Þ and controls ðn ¼ 530Þ. RANTES-403 genotype
frequencies were significantly different in cases and controls ðv2 ¼ 4:17; p ¼ 0:041Þ,
as were A allele carrier frequencies (36.01% vs. 30.19%, OR¼ 1.30 [95%-
CI¼ 1.06–1.60], p ¼ 0:010). By multivariate analysis, RANTES A-403 retained signifi-
cant association with CAD ðv2 ¼ 8:40; p ¼ 0:0038Þ. RANTES A-403 was associated with
increased ACS prevalence (OR¼ 1.36 [95%-CI¼ 1.08–1.71], p ¼ 0:0073). MCP-1 G-
2518, SDF-1b A801, and CCR5 D32 were not associated with CAD.
Conclusions RANTES A-403 was associated with CAD independently from conventional
risk factors and CRP or fibrinogen as inflammatory biomarkers. The association was
enhanced in smokers and ACS, conditions where platelet activation and inflammation
predominate. RANTES A-403 may increase genetic susceptibility to CAD.c 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.
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Arteriosclerosis is a multi-factorial condition which is
determined both by environmental and genetic factors,
and involves a strong inflammatory component.1 Cell
adhesion and signalling interactions between circulating
leucocytes and the endothelium are key events in the
recruitment of leucocytes to inflammatory foci. While
beneficial in defense against infection and cancer, in-
teractions between leucocytes and endothelium initiate
arterial lesion formation. In response to chemoattractant
signals, monocytes and T-cells adhere to inflamed en-
dothelium, transmigrate into the sub-endothelial space,
recognise intra-lesional antigens such as oxidised low-
density lipoproteins (ox-LDL), and acquire an activated
phenotype in the vessel wall.2
Chemoattractant peptides (chemokines) regulate
leucocyte trafficking in inflammatory diseases.3 The C–C
chemokine Regulated upon Activation, Normal T-cell
Expressed and Secreted (RANTES), monocyte chemo-
attractant protein-1 (MCP-1), and stromal cell-derived
factor-1b (SDF-1bÞ chemokines have been implicated in
atherogenesis. RANTES is a potent chemoattractant for
monocytes, lymphocytes, eosinophils, and basophils.
RANTES expression has been demonstrated in T-cells in
human atherosclerotic plaques,4 as well as in lympho-
cytes, macrophages, endothelial cells, and vascular
smooth muscle cells in transplant-associated arterio-
sclerosis.5 Mice deficient in the RANTES gene show im-
paired T-cell and monocyte recruitment to inflammatory
sites.6 MCP-1 is a potent chemoattractant for monocytes
and memory T-cells, and an activator for monocytes/
macrophages within arterial lesions.7 Mice deficient in
either the MCP-1 or in the C–C chemokine receptor
(CCR)-2 gene that encode the main receptor for MCP-1
show reduced arterial lesion formation when crossed
with arteriosclerosis-prone mice deficient in the LDL
receptor gene.8;9 These findings support a central role for
MCP-1 in atherogenesis. SDF-1b is a potent platelet ag-
onist that has been implicated in lymphocyte arrest on
inflamed endothelium.10
Recently, common polymorphisms in the RANTES,
MCP-1, SDF-1b, and CCR5 genes have been associated
with functional and biological effects. The A-403 variant
in the promoter region of the RANTES gene resulted in
up to 8-fold increased constitutive transcriptional ac-
tivity after transient transfection of the human mast-
cell line HMC-1 and the T-cell line Jurkat with reporter
vectors driven by either the mutant or the reference
RANTES promoter.11 Clinical associations of RANTES
A-403 with inflammatory diseases such as atopic derma-
titis,11;12 asthma,12 polymyalgia rheumatica,13 sarcoido-
sis,14 diabetic nephropathy,15 as well as susceptibility to
HIV infection and disease progression16 have been
reported.
The G-2518 variant in the distal regulatory region of
the MCP-1 gene resulted in increased MCP-1 expression in
human peripheral blood mononuclear cells (PBMC) by
2-fold upon IL-1 stimulation.17 An association between
MCP-1 G-2518 homozygosity and coronary artery disease
(CAD) was also reported recently.18The A801 variant in the 30 untranslated region of the
SDF-1b gene has been associated with genetic restriction
of AIDS pathogenesis,19 as well as with enhanced CD34þ
progenitor cell mobilisation from the bone marrow.20
Although it has been proposed that the A801 variant may
enhance SDF-1b bioavailability,19 available data on its
effect on SDF-1b expression are conflicting.21–23
The D32 deletion mutation in the gene encoding
CCR5, a receptor for RANTES, results in a frameshift and
premature termination of transcript translation, pre-
venting expression of the receptor molecule on cell
surfaces.24 Associations of CCR5 D32 with resistance to
HIV infection,24 reduced severity of asthma25 and rheu-
matoid arthritis,26 as well as decreased risk of premature
myocardial infarction have been reported.27
These findings suggest functional gene variants in
chemokines and chemokine receptors may affect ge-
netic susceptibility to inflammatory diseases, most
likely by modulating leucocyte recruitment and acti-
vation in inflammatory foci. We hypothesised that
functional polymorphisms in the RANTES, MCP-1, SDF-
1b, and CCR5 genes influence the development of
coronary artery lesions. To test this hypothesis, we
genotyped a large cohort studied by coronary angiog-
raphy, and we correlated genotypic and angiographic
findings. A significant association with angiographically
detectable coronary artery lesions was found for
RANTES G-403A, but not for the other candidate gene
polymorphisms.Methods
Study population
We genotyped the LUdwigshafen Risk and Cardiovascular
health (LURIC) cohort of 3316 individuals who underwent
coronary angiography because of chest pain or non-
invasive tests consistent with myocardial ischaemia.28 All
individuals were Caucasians born in Germany from par-
ents of German ancestry. Three thousand two hundred
and twenty four subjects were included in the analysis
after exclusion of 92 individuals due to incomplete an-
giographic data ðn ¼ 49Þ, clinical evidence of arterial
disease including stroke, carotid artery stenosis and se-
vere peripheral artery disease (defined by a history of
intermittent claudication, angiographic documentation
of lumen obstruction, aneurysm of the abdominal aorta,
or a history of peripheral arterial intervention for ath-
erosclerotic disease) in patients with normal coronary
angiograms ðn ¼ 39Þ, a history of myocardial infarction in
patients with normal coronary angiograms ðn ¼ 2Þ, or
missing genetic data ðn ¼ 2Þ.
Angiographic classification
Angiographic criteria defining CAD cases vs. controls
were as follows: (1) lumen reduction P 20% on one or
more major epicardial coronary arteries; (2) lumen re-
duction 10–19% in three or more (out of 15) coronary
artery segments. Mild coronary lesions were defined as
Table 1 Clinical characteristics of controls and cases, and their associations with CAD (univariate analysis)
Characteristic n Controls, n ¼ 530 Cases, n ¼ 2694 p-value
Age: years 3224 56.9±11.9 63.8±9.9 \0.0001
Male gender, (%) 3224 51.3 73.9 \0.0001
Smoker, (%) 3224 46.4 67.7 \0.0001
Arterial hypertension, (%) 3224 42.1 61.9 \0.0001
Type 2 diabetes, (%) 3127 7.5 22.5 \0.0001
Hypercholesterolaemia, (%) 3224 36.6 68.4 \0.0001
Hypertriglyceridaemia, (%) 3223 39.1 48.8 \0.0001
Low HDL cholesterol, (%) 3223 44.3 55.2 \0.0001
Waist-to-hip ratio 3184 0.93±0.08 0.97±0.07 \0.0001
Fibrinogen: mg/dL 3221 347.5±74.8 406.4±109.9 \0.0001
C reactive protein: mg/L 3218 335 (295–392) 388 (327–463) \0.0001
Nominal variables (definitions: see “Methods”) are percentages. Age, WHR, and fibrinogen are mean values±SD; CRP are median values (25–75
percentiles). Missing data in controls for diabetes ðn ¼ 8Þ, WHR ðn ¼ 5Þ, and fibrinogen ðn ¼ 1Þ. Missing data in cases for diabetes ðn ¼ 89Þ, TG
ðn ¼ 1Þ, HDL-C ðn ¼ 1Þ, WHR ðn ¼ 35Þ, fibrinogen ðn ¼ 2Þ, and CRP ðn ¼ 6Þ.
1440 E. Simeoni et al.<50% lumen narrowing and moderate to severe coronary
artery stenoses as P 50% lumen narrowing.
Clinical data
Clinical characteristics of cases and controls are shown in
Table 1. Diabetes was defined according to the new ADA
and WHO criteria29;30 by presence of one or more of the
following criteria: (1) treatment with hypoglycaemic
agents; (2) two diagnostic tests showing high blood glu-
cose levels (fasting plasma glucose P 126 mg/dL and/or
2-h plasma glucose P 200 mg/dL during an oral glucose
tolerance test according to the WHO criteria30); (3) hi-
story of diabetes confirmed by at least one diagnostic
test performed during the study. Subjects ðn ¼ 97Þ with a
single high blood glucose level (no confirmatory test)
were not assigned an unequivocal diabetes status. Hy-
pertension was defined as a supine systolic blood pres-
sure P 140 mmHg and/or diastolic pressure P 90
mmHg (average from three consecutive measurements
after 10 min of rest). Hypercholesterolaemia was defined
as fasting cholesterol P 240 mg/dL or treatment with
lipid-lowering drugs. High triglycerides (TG) were P 150
mg/mL. Low HDL-cholesterol (HDL-C) was <35 mg/mL in
males and \45 mg/mL in females. Fibrinogen was
measured by the STA fibrinogen/STA Stago Kit (Stago
Diagnostica/Roche). C-reactive protein (CRP) was mea-
sured using a mAb nephelometric assay (N LATEX CRP
mono; Dade Behring). Among the 3224 individuals in-
cluded in the analysis, data sampling was incomplete
with respect to TG and HDL-C in 1 subject each, and to
fibrinogen, CRP, and waist-to-hip ratio (WHR) in 3, 6, and
40 patients, respectively.
Acute coronary syndromes
In addition to an analysis of the presence of any angio-
graphic lesion (CAD) as the primary endpoint, the preva-
lence of acute coronary syndromes (ACS) was analysed as
a secondary endpoint reflecting functionally active le-
sions resulting in major coronary events in CAD patients.
ACS were defined as unstable angina or acute myocardial
infarction, with or without ST-segment elevation, in ac-cordance with the Joint European Society of Cardiology/
American College of Cardiology Committee.31
Genotyping
Genotyping of RANTES G-403A, MCP-1 A-2518G, and SDF-
1b G801A polymorphisms was performed by restriction
fragment length polymorphism (RFLP)-PCR as de-
scribed,13;17;19 with a minor modification for RANTES G-
403A. This modification consisted of the change of a
single base (capital letter, underlined) within the 3’
primer (50-gttcctgcttattcattacagatcGta-30) to create a
new restriction digestion site for better discrimination of
the PCR fragments. Because genotype frequencies of
RANTES-403 did not comply with Hardy–Weinberg equi-
librium (HWE) proportions in the control group (see:
“Results”), genotyping was repeated twice in this group
using higher concentrations of restriction enzyme to rule
out partial digestion, and using an improved method
for RFLP with a modified 50 primer (50-caatgcccagc-
tcagatcaactgcctc-30). Genotyping of CCR5 D32 was
performed by PCR, as described.24 Technicians and in-
vestigators were blinded with respect to case-control
status. Two investigators scored gels independently and
unclear positions were repeated. Genotype results were
typed twice into data files to avoid errors in recording.
Statistical analysis
Power calculations with a pre-set level of significance
ða ¼ 0:05Þ had been calculated for equal numbers of
cases and controls according to Fleiss et al.,32 in the
LURIC project (see LURIC study design,28 Appendix II).
For an unequal number of cases ðn ¼ 2694Þ and controls
ðn ¼ 530Þ, the power to detect a 6% or 7% difference in
genotype/allele frequencies for a two-sided test with a
level of significance of p ¼ 0:05 was 74% or 86%, re-
spectively. Data are shown as frequencies or
means±standard deviation (SD). CRP did not have a
normal standard distribution and was log-transformed for
analysis. The JMP program (version 5; SAS Institute, Cary,
NC) was used for statistical analysis. Frequencies were
compared with the Pearson v2-test; means were com-
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ANOVA test. Gene counting method estimated allele
frequencies, and the v2 analysis was used to test for
deviations of genotype proportions from HWE. The Ar-
mitage’s test for trend in proportions (does not assume
HWE) was used for statistical analysis of genotype and
allele carrier frequencies according to Sasieni,33 as pro-
posed by Xu et al.34 In addition, the variance of differ-
ences in allele frequencies was determined using the
method by Schaid and Jacobsen.35 Odds ratios for ge-
notype analysis were calculated according to Sasieni.33
Correction for multiple testing was performed by Bon-
ferroni adjustment. The Cochran–Mantel–Haenszel
method was used to test association of RANTES A-403
with CAD after stratification for cigarette smoking, age,
and gender. The independent contribution of RANTES A-
403 to CAD was determined by nominal logistic analysis,
with CAD as the dependent variable, using three differ-
ent models with increasingly conservative character: (1)
conventional coronary risk factors including age, male
gender, smoking, hypertension, diabetes, hypercho-
lesterolaemia, low HDL-C, high TG, and WHR were en-
tered as co-variates; (2) in addition to those traditional
risk factors, CRP was entered as a co-variate; (3) in ad-
dition to traditional risk factors and CRP, fibrinogen was
also entered as a co-variate. Age, WHR, CRP, and fi-
brinogen were analysed as continuous variables that
satisfied the assumption of linearity. This assumption was
checked by: (1) sub-dividing each continuous variable
into five sub-groups, corresponding to the each 20th
percentiles of the distribution; (2) calculating the logits
of CAD probabilities for each sub-group; (3) analysing the
linearity of the logit vs. the sub-divided variable by
simple linear regression (age, r2 ¼ 0:95; WHR, r2 ¼ 0:91;
CRP, r2 ¼ 0:99; fibrinogen, r2 ¼ 0:97). To test the influ-
ence of gene–gene interaction of MCP-1 A-2518G, SDF-
1b G801A, and CCR5 D32 polymorphisms with RANTES
G-403A and CAD, a multivariate model with interaction
terms (MCP-1 A-2518G*RANTES G-403A, SDF-1b
G801A*RANTES G-403A, and CCR5 D32*RANTES G-403A)Table 2 Clinical characteristics of controls and cases in carriers
Characteristics Controls, ðnÞ
GG (n ¼ 370) AGþA
Age: years, ðnÞ 57.1±11.6 (370) 56.5±
Male gender, % ðnÞ 51.1 (189) 51.9 (8
Smoker, % ðnÞ 48.8 (179) 41.9 (6
Arterial hypertension, % ðnÞ 42.7 (158) 40.6 (6
Type 2 diabetes, % ðnÞ 6.0 (22) 10.8 (1
Hypercholesterolemia, % ðnÞ 37.8 (140) 33.7 (5
Hypertriglyceridemia, % ðnÞ 39.5 (146) 38.1 (6
Low HDL cholesterol, % ðnÞ 43.2 (160) 46.9 (7
Waist to hip ratio ðnÞ 0.93±0.08 (367) 0.93±
Fibrinogen, mg/dL ðnÞ 344.7±73.2 (369) 353.7±
CRP, mg/L [25–75 percentiles] ðnÞ 335 [294–390] (370) 338 [29
Age, WHR, and fibrinogen are mean values±SD; CRP are median values [
ðn ¼ 2Þ and WHR ðn ¼ 2Þ in controls, and for diabetes ðn ¼ 33Þ, WHR ðn ¼ 18Þ
diabetes ðn ¼ 6Þ, WHR ðn ¼ 3Þ, and fibrinogen ðn ¼ 1Þ in controls, and for dia
ðn ¼ 2Þ, and CRP ðn ¼ 4Þ in cases.was used. We adopted a significance level of p < 0:05 for
this exploratory study.Results
Angiographic results
Based on coronary angiographic criteria, 3224 subjects of
the LURIC cohort included in the analysis were sub-
divided into cases ðn ¼ 2694Þ with abnormal angiograms
and controls ðn ¼ 530Þ with normal angiograms. Among
cases, the majority ðn ¼ 2231Þ showed moderate to se-
vere lumen reduction (P 50%) in one ðn ¼ 620Þ, two
ðn ¼ 623Þ, or three ðn ¼ 988Þ major epicardial coronary
arteries. A minority of cases presented with 0-vessel
disease (<50% stenosis; n ¼ 463) defined as mild angio-
graphic abnormalities with lumen reduction of 20–49% of
at least one major coronary artery ðn ¼ 336Þ or minor
narrowings (10–19%) of P 3 coronary artery segments
ðn ¼ 127Þ.
Associations between clinical characteristics and
CAD
Patients with CAD presented with the typical changes in
the cardiovascular risk profile when compared to sub-
jects without CAD (all p < 0:0001; Table 1).
Genotypic data and HWE
Genotype frequencies for RANTES-403 complied with
HWE both in the study population as a whole and in cases
(data not shown), but deviated from it in controls
ðv2 ¼ 4:49; p ¼ 0:034Þ. The true Type-I error rate ðdÞ and
the fraction of maximum discrepancy with respect to the
HWE model (f, where HWE: f ¼ 0; maximum discrep-
ancy: f ¼ 1:0), calculated according to Schaid and Jac-
obsen,35 were modest ðd ¼ 0:00239; f ¼ 0:015Þ. Odds
ratios for genotype analysis were calculated according to(AGþAA) and non-carriers (GG) of RANTES A-403
Cases, ðnÞ
A (n ¼ 160) GG (n ¼ 1724) AGþAA (n ¼ 970)
12.6 (160) 63.5±10.1 (1724) 64.3±9.5 (970)
3) 75.1 (1294) 71.9 (697)
7) 68.8 (1187) 65.8 (638)
5) 61.9 (1068) 61.7 (599)
7) 21.8 (364) 23.7 (222)
4) 68.7 (1184) 68.0 (660)
1) 50.0 (861) 46.6 (452)
5) 55.5 (957) 54.6 (530)
0.08 (158) 0.97±0.07 (1707) 0.96±0.08 (952)
78.1 (160) 403.5±108.6 (1722) 411.5±112.0 (970)
7–396] (160) 384 [326–460] (1720) 393 [332–469] (968)
25–75 percentiles]. Missing data in carriers of the A allele for diabetes
, and CRP ðn ¼ 2Þ in cases. Missing data in non-carriers of the A allele for
betes ðn ¼ 56Þ, TG ðn ¼ 1Þ, low HDL-C ðn ¼ 1Þ, WHR ðn ¼ 17Þ, fibrinogen
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1442 E. Simeoni et al.Sasieni.33 Genotype frequencies for MCP-1-2518, SDF-1b
801, and CCR5 D32 were in HWE in both cases and con-
trols (data not shown).
Association between RANTES A-403 and coronary
risk factors
Clinical characteristics of carriers (AG/AA) and non-car-
riers (GG) of the RANTES A-403 allele were comparable
(p > 0:05; Table 2). In the study population as a whole,
only plasma fibrinogen was correlated with RANTES-403
genotype and allele carrier frequencies (F ratio¼ 3.47,
p ¼ 0:0310 and t ¼ 2:59; p ¼ 0:0098, respectively).Association between RANTES A-403 and CAD
Genotype and allele frequencies of RANTES-403, as well
as allele carrier frequencies of RANTES A-403, were sig-
nificantly different between cases and controls (Table 3).
The analysis of allelic frequencies using the method
by Schaid and Jacobsen35 that corrects for deviations
from HWE yielded Z ¼ 2:04 ðp ¼ 0:041Þ. For comparison,
assuming a HWE model would yield ZHWE ¼ 2:06 ðp ¼
0:040Þ, consistent with a minor difference between the
HWE and non-HWE models for this analysis. After sub-
division of cases based on coronary lesion severity, allele
carrier frequencies of RANTES A-403 were significantly
increased both in cases with moderate to severe lesions
(P 50%) and in those with mild lesions (<50%), as com-
pared to controls (Table 4). Data stratification for gender
and age revealed no significant effect of these parame-
ters on the association between RANTES A-403 and CAD
(data not shown). After data stratification for cigarette
smoking, the significant association between RANTES
A-403 and CAD was slightly enhanced (genotype and A
allele carrier frequencies: v2 ¼ 9:41; p ¼ 0:0090 and v2 ¼
8:20; p ¼ 0:0042, respectively).RANTES A-403 is an independent predictor of
CAD
Genotype and allele frequencies of RANTES A-403 re-
tained significant association with CAD, independent of
conventional risk factors, in a multivariate model with
conventional coronary risk factors entered as co-variates
(first model; Table 5). The association was maintained
when CRP was entered as a co-variate in addition to
conventional risk factors (second model; v2 ¼ 6:65;
p ¼ 0:036 and v2 ¼ 6:47; p ¼ 0:011 for genotype and
allele frequencies, respectively), or when CRP and fi-
brinogen were both entered as additional co-variates
(third model; v2 ¼ 6:19; p ¼ 0:045 and v2 ¼ 6:02; p ¼
0:014 for genotype and allele frequencies, respectively).Association between RANTES A-403 and ACS
Among CAD cases, ACS occurred in 1032 patients,
whereas 1662 patients did not suffer from ACS. Genotype
frequencies of RANTES-403 were significantly different
Table 4 Genotype and allele frequencies of RANTES A-403 with respect to CAD severity
Group Genotypes frequencies, % ðnÞ A allele carrier frequencies, %
GG AG AA v2 p OR v2 p OR (95% CI)
Controls 69.8 (370) 25.8 (137) 4.3 (23) 30.2
CAD\50% 61.6 (285) 33.7 (156) 4.7 (22) 5.67 0.017 1.24 38.4 7.50 0.006 1.44
(1.10–1.90)
CAD P 50% 64.5 (1439) 31.6 (706) 3.9 (86) 3.16 0.075 1.11 35.5 5.35 0.021 1.27
(1.03–1.57)
Data are shown for subsets with mild (lumen reduction: <50%) or moderate to severe CAD (lumen reduction: P 50%)(Calculation of OR, see 33).
Table 5 Nominal logistic fit, with CAD as the dependent variable (first model; see “Methods”)
Genotype analysis A allele carrier analysis
Source of variation DF R2 L-R v2 p value DF R2 L-R v2 p value
Multivariate model (n ¼ 3086)
All variables 11 0.24 665.9 <0.0001 10 0.24 665.6 <0.0001
Age (yr) 1 156.1 <0.0001 1 156.2 <0.0001
Gender 1 60.8 <0.0001 1 60.8 <0.0001
Smoker 1 61.7 <0.0001 1 61.7 <0.0001
Arterial hypertension 1 23.6 <0.0001 1 23.6 <0.0001
Type 2 diabetes 1 23.6 <0.0001 1 23.6 <0.0001
Waist to hip ratio 1 1.98 0.16 1 2.03 0.15
Hypercholesterolemia 1 153.1 <0.0001 1 153.2 <0.0001
Hypertriglyceridemia 1 0.43 0.51 1 0.44 0.51
Low HDL cholesterol 1 21.2 <0.0001 1 21.2 <0.0001
RANTES-403 polymorphism 2ð#Þ 8.64 0.013 1ðÞ 8.40 0.0038
Type of analysis: ð#Þ3-class (GG¼ 0, AG¼ 1, and AA¼ 2); ðÞ2-class (GG¼ 0 and AG+AA¼ 1). Due to incomplete data in a small number of subjects
(see “Methods”), the multivariate model included 3086 subjects with complete data.
1443Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosisbetween cases with ACS and controls ðv2 ¼ 5:17;
OR ¼ 1:19; p ¼ 0:023Þ, but not between cases without
ACS and controls ðv2 ¼ 2:69; OR ¼ 1:10; p ¼ 0:10Þ. Simi-
larly, allele carrier frequencies of RANTES A-403 were
significantly increased in cases with ACS compared with
controls (37.02% vs. 30.19%; v2 ¼ 7:20; OR ¼ 1:36 [95%-
CI¼ 1.08–1.71], p ¼ 0:0073), even after Bonferroni ad-
justment for multiple testing. In contrast, A allele carrier
frequencies were only slightly increased in cases without
ACS (35.38%; v2 ¼ 4:82; OR ¼ 1:27 [95%-CI¼ 1.02–1.57],
p ¼ 0:028).Table 6 Genotype, allele, and allele carrier frequencies of MCP-1
controls and cases
Genotype frequencies, n (%)
Polymorphism Group Genotype 1–1* Genotype 1
MCP-1 A-2518G Controls 288 (54.5) 207 (39.2)
Cases 1423 (52.8) 1068 (39.7)
SDF-1b G808A Controls 350 (66.2) 159 (30.1)
Cases 1709 (63.5) 885 (32.9)
CCR5 D32 Controls 423 (80.1) 99 (18.7)
Cases 2093 (78.1) 553 (20.6)
(*) 1, frequent allele and 2, rare allele. Missing data for MCP-1 A-2518G:
CCR5 D32: n ¼ 2 controls and 13 cases. p > 0:10 in cases vs. controls for e
allele carrier frequencies between cases and controls.Lack of association between MCP-1 G-2518,
SDF-1b A801, CCR5 D32, and CAD
Genotype, allele, and allele carrier frequencies of MCP-
1-2518, SDF-1b 801, and CCR5-32 were not significantly
different in cases and controls (Table 6). In disagreement
with a previous report,27 CCR5 D32 was not correlated
with premature myocardial infarction (data not shown).
No significant gene–gene interaction of the four poly-
morphisms with respect to CAD risk was observed (data
not shown).A-2518G, SDF-1b G801A, and CCR5 D32 gene polymorphisms in
Allele 2*
frequencies, %
Allele 2* carrier
frequencies, %
–2* Genotype 2–2*
33 (6.2) 25.8 45.4
202 (7.5) 27.3 47.2
20 (3.8) 18.8 33.8
96 (3.6) 20.0 36.5
6 (1.1) 10.5 19.9
35 (1.3) 11.6 21.9
n ¼ 2 controls and 1 case; SDF-1b G808A: n ¼ 1 control and four cases;
ach polymorphism with respect to differences in genotype, allele, and
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Gene polymorphisms that modify expression and/or bio-
availability of chemokines and their cellular receptors
may affect leucocyte trafficking in inflammatory dis-
eases, including arteriosclerosis. In our case-control
study of n ¼ 3224 subjects, RANTES A-403, but not the
other three gene variants studied, was significantly as-
sociated with CAD. Carriers of the A allele were at in-
creased risk of developing angiographically detectable
coronary lesions compared with individuals homozygous
for the G allele. The association was stronger in patients
with mild (<50%) coronary lesions ðp ¼ 0:017Þ and in
those with ACS ðp ¼ 0:023Þ. After Bonferroni adjustment
for multiple testing of the four gene polymorphisms, the
frequency of carriers of the A allele remained signifi-
cantly increased in CAD patients. The association be-
tween RANTES A-403 and CAD was enhanced in cigarette
smokers. Finally, RANTES A-403 remained significantly
associated with CAD after multivariate adjustment for
conventional risk factors and for CRP and fibrinogen, two
biomarkers of systemic inflammation associated with
CAD.36;37
Thus, we were able to replicate recent results from
Hungary showing an increased frequency of the RANTES
A-403 allele in patients undergoing coronary artery by-
pass surgery.18 However, the statistical significance in
this smaller cohort ðn ¼ 628Þ was borderline
(p ¼ 0:052; OR ¼ 1:33 [95%-CI¼ 1.00–1.77]). Of note,
this odds ratio is closely comparable to the one obtained
in the present study. Obviously, replicating results in
independent cohorts is crucial for establishing a genetic
association.
The biological mechanism underlying this genetic as-
sociation most likely is increased gene expression from
the RANTES A-403 promoter variant.11 RANTES expres-
sion is differentially regulated in many tissues. Several
putative cis-acting elements have been described in the
RANTES promoter region.38 The A-403 variant introduces
a new consensus binding site for the GATA transcription
factor family. This variant has been associated with en-
hanced RANTES promoter activity in human T-cell and
mast cell lines, which express GATA binding proteins, but
not in epithelial cells, which do not express these pro-
teins.11 Because megakaryocytes constitutively express
both RANTES and GATA binding proteins,39 RANTES pro-
duction and release by platelets might be enhanced in
carriers of the A-403 allele. RANTES stored in platelet
secretory vesicles is released upon platelet activation
and immobilised on the surface of inflamed endothe-
lium,40–42 where it promotes shear-resistant monocyte
arrest and trans-endothelial migration,40;43–45 while
generating a critical signal for chemokine production by
monocytes.46 RANTES deposition on the luminal surface
of carotid arteries has been demonstrated in apolipo-
protein E-deficient mice with early atherosclerotic le-
sions in vivo, as well as in human atherectomy samples.40
The RANTES antagonist Met-RANTES inhibited monocyte
recruitment on carotid endothelium, neointima forma-
tion and macrophage accumulation after arterial injury,
as well as atherosclerosis progression in uninjured ar-teries in apolipoprotein E-deficient mice.40;46;47 These
findings suggest an important role for RANTES in vascular
disease, potentially explaining the enhanced association
between RANTES A-403 and CAD in conditions charac-
terised by platelet activation, such as smoking and ACS.
Recently, RANTES A-403 has been associated with
several inflammatory diseases.11–15 Polymorphisms in
other chemokine genes have also been associated with
CAD. Fraktalkine and its receptor, CX3CR1, which are
expressed in human plaques,48 have been implicated in
atherogenesis.49 An association between the I249 variant
of CX3CR1 and reduced endothelial dysfunction and CAD
lesions was reported.50 The loss-of-function mutation
CX3CR1-M280 was associated with cardiovascular pro-
tection in Framingham participants.51 The rare Val64Ile
polymorphism in the CCR2 gene coding for the main MCP-
1 receptor was associated with reduced coronary calci-
fications in one study,52 and with premature myocardial
infarction (but not coronary lesions) in another study.53
As mentioned, MCP-1 G-2518 homozygosity was also as-
sociated with CAD.18 However, this association was not
replicated in the present study in a larger cohort, nor was
the reported protection against premature myocardial
infarction by CCR5 D32.27
A methodological aspect of the present study that
deserves discussion, like in many case-control associa-
tion studies, is the appropriateness of the control group.
Because angiography is relatively insensitive for early
lesions that do not impact on the vascular lumen, early
lesions undetectable by angiography could not be ruled
out in controls, nor was coronary microvascular dys-
function. Nevertheless, coronary angiography remains a
gold standard for the diagnosis of CAD, and it is well
known that the future incidence of cardiac events is low
in subjects with normal coronary angiograms. Another
issue that deserves consideration is the departure of
RANTES-403 genotypes from HWE proportions in controls
ðv2 ¼ 4:49; p ¼ 0:034Þ, the number of AA homozygous
subjects being higher than expected. Apparent violations
of HWE might arise because of errors in genotyping. A
literature survey found that 16 out of 133 single nucle-
otide polymorphisms (12%) from 75 case-control studies
deviated from HWE.34 Therefore, genotyping was re-
peated three times (with two different methods) to
carefully rule out genotyping errors in controls. Another
potential cause for deviations from HWE is ethnic di-
versity within the population. The LURIC study was re-
stricted to native Germans of German ancestry living in
the Rhine valley area (a region where >95% are Cauca-
sians of German descent and where second and third-
generation family members are often alive) in order to
limit ethnic heterogeneity and to enhance access to
family members. All other gene polymorphisms tested in
this cohort in the present and previous studies were in
HWE, also consistent with limited ethnic heterogeneity.
Thus, no explanation could be found for the departure
from HWE in controls. A comparison of our data with
those from the Hungarian cohort18 (complying with HWE)
shows almost identical frequencies of control subjects
homozygous for the frequent G allele (69.1% vs. 69.8% in
LURIC) and, hence, of controls carrying the A allele.
1445Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosisStated differently, frequencies of carriers of the A allele
in controls, which significantly differed from those in
cases in our study ðv2 ¼ 6:58; p ¼ 0:010Þ, were closely
comparable in the two studies. It also should be em-
phasised that this analysis, like the one of genotype
frequencies, was performed using statistical tests that
do not assume HWE.33 Moreover, allelic frequencies were
analysed using the test by Schaid and Jacobsen35 that
corrects for deviations from HWE. This test also revealed
that the true Type-I error rate and the fraction of max-
imum discrepancy with the HWE model were modest,
corroborating the validity of our statistical data.
In conclusion, the RANTES A-403 allele was associ-
ated with CAD independently from conventional car-
diovascular risk factors and from CRP and fibrinogen,
two biomarkers of vascular inflammation. The associa-
tion was enhanced in smokers and ACS, two conditions
that are accompanied by platelet activation and vascu-
lar inflammation. Our findings are consistent with bio-
logical effects of Met-RANTES in experimental models of
arteriosclerosis.40;46;47 Novel non-peptide, orally bio-
available RANTES antagonists that have been success-
fully tested in heart transplantation54 and HIV models55
might also prove effective in preventing cardiovascular
disease.Acknowledgements
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